...
首页> 外文期刊>Journal of toxicology >Cardiorenal Effects of Newer NSAIDs (Celecoxib) versus Classic NSAIDs (Ibuprofen) in Patients with Arthritis
【24h】

Cardiorenal Effects of Newer NSAIDs (Celecoxib) versus Classic NSAIDs (Ibuprofen) in Patients with Arthritis

机译:新型NSAIDs(塞来昔布)与经典NSAIDs(布洛芬)在关节炎患者中的肾脏作用

获取原文
           

摘要

Background. Arthritis is a common condition that co-exists in the elderly population. This condition leads to frequent administration of comorbid analgesics especially non steroidal anti-inflammatory drugs (NSAIDs).Aim. To study cardiorenal toxicity of celecoxib versus ibuprofen in arthritic patients.Subjects and Methods. Seven hundred ninety-wo arthritic patients were enrolled in the study for 6 months. Three hundred ninety-six patients administered celecoxib 400 mg twice a day; 396 patients administered ibuprofen 300 mg three times a day. Effects measured included investigator-reported hypertension, edema, or congestive heart failure, increases in serum creatinine or reduction in serum creatinine clearance, and changes in serum electrolytes.Results. Celecoxib was associated with significant (P<.05) lower incidence of hypertension and edema in comparison with ibuprofen. Systolic hypertension occurred significantly less (P<.05) with celecoxib compared with ibuprofen. Serum creatinine was significantly increased (P<.05) in patients treated with ibuprofen in comparison with celecoxib. Creatinine clearance was significantly lower (P<.05) in cases treated with ibuprofen in comparison to celecoxib. Nonsignificant changes in serum body electrolytes occurred.Conclusion. The most important finding of this study was the lowering incidence of cardiorenal toxicity of celecoxib in comparison with ibuprofen.
机译:背景。关节炎是老年人中共存的常见疾病。这种情况会导致并发镇痛药的频繁使用,尤其是非甾体类抗炎药(NSAIDs)。研究塞来昔布和布洛芬对关节炎患者的心脏肾毒性。 790名关节炎患者参加了为期6个月的研究。 396例患者每天两次服用celecoxib400μmg。 396名患者每天3次服用布洛芬300mg。测量的影响包括研究者报告的高血压,水肿或充血性心力衰竭,血清肌酐升高或血清肌酐清除率降低以及血清电解质变化。与布洛芬相比,塞来昔布与高血压和水肿的发生率显着降低(P <.05)。与布洛芬相比,塞来昔布的收缩期高血压发生率显着降低(P <.05)。与塞来昔布相比,布洛芬治疗的患者血清肌酐显着增加(P <.05)。与塞来昔布相比,布洛芬治疗组的肌酐清除率明显更低(P <.05)。血清电解质水平无明显变化。这项研究最重要的发现是与布洛芬相比,塞来昔布的心脏肾毒性发生率降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号